141 related articles for article (PubMed ID: 10847114)
1. Dofetilide for atrial fibrillation.
Med Lett Drugs Ther; 2000 May; 42(1078):41-2. PubMed ID: 10847114
[No Abstract] [Full Text] [Related]
2. Chemical cardioversion of atrial fibrillation with intravenous dofetilide.
Sedgwick ML; Lip G; Rae AP; Cobbe SM
Int J Cardiol; 1995 Apr; 49(2):159-66. PubMed ID: 7628887
[TBL] [Abstract][Full Text] [Related]
3. Dofetilide for atrial fibrillation.
Rubin SA
N Engl J Med; 2000 Jan; 342(4):289-90. PubMed ID: 10660387
[No Abstract] [Full Text] [Related]
4. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
[TBL] [Abstract][Full Text] [Related]
5. Dofetilide: a new class III antiarrhythmic agent.
Roukoz H; Saliba W
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
[TBL] [Abstract][Full Text] [Related]
6. Dofetilide (Tikosyn): a new drug to control atrial fibrillation.
Saliba WI
Cleve Clin J Med; 2001 Apr; 68(4):353-63. PubMed ID: 11326815
[TBL] [Abstract][Full Text] [Related]
7. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
[TBL] [Abstract][Full Text] [Related]
8. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
Singh SN
Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
[TBL] [Abstract][Full Text] [Related]
9. Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.
Nagra BS; Ledley GS; Kantharia BK
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):191-5. PubMed ID: 16211208
[TBL] [Abstract][Full Text] [Related]
10. Dofetilide-induced long QT and torsades de pointes.
Aktas MK; Shah AH; Akiyama T
Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063
[TBL] [Abstract][Full Text] [Related]
11. Dofetilide: is the treatment worse than the disease?
Lauer MR
J Am Coll Cardiol; 2001 Mar; 37(4):1106-10. PubMed ID: 11263616
[No Abstract] [Full Text] [Related]
12. Dofetilide: a new pure class III antiarrhythmic agent.
Falk RH; Decara JM
Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
[TBL] [Abstract][Full Text] [Related]
13. Considerations for dofetilide use in the elderly.
Crist LW; Dixon DL
Consult Pharm; 2014 Apr; 29(4):270-4. PubMed ID: 24704896
[TBL] [Abstract][Full Text] [Related]
14. Dofetilide for the treatment of atrial fibrillation in patients with congestive heart failure.
Torp-Pedersen C; Moller M; Kober L; Camm AJ
Eur Heart J; 2000 Aug; 21(15):1204-6. PubMed ID: 10924306
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
Suttorp MJ; Polak PE; van 't Hof A; Rasmussen HS; Dunselman PH; Kingma JH
Am J Cardiol; 1992 Feb; 69(4):417-9. PubMed ID: 1734660
[No Abstract] [Full Text] [Related]
16. Atrial fibrillation in heart failure.
Stevenson WG; Stevenson LW
N Engl J Med; 1999 Sep; 341(12):910-1. PubMed ID: 10486424
[No Abstract] [Full Text] [Related]
17. Dofetilide-Induced Severe Hepatotoxicity.
Subedi R; Dean RK; Dhamoon AS
Am J Ther; 2018; 25(6):e783-e784. PubMed ID: 29912716
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter.
Lindeboom JE; Kingma JH; Crijns HJ; Dunselman PH
Am J Cardiol; 2000 Apr; 85(8):1031-3. PubMed ID: 10760352
[No Abstract] [Full Text] [Related]
19. Safety and effectiveness of dofetilide for conversion of atrial fibrillation and nesiritide for acute decompensation of heart failure: a report from the cardiovascular and renal advisory panel of the Food and Drug Administration.
Grines CL
Circulation; 2000 May; 101(21):E200-1. PubMed ID: 10831533
[No Abstract] [Full Text] [Related]
20. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation.
Torp-Pedersen C; Brendorp B; Køber L
Expert Opin Investig Drugs; 2000 Nov; 9(11):2695-704. PubMed ID: 11060831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
